Dec 15, 2025 • Benzinga
BULLISH
Gilead's Experimental Combo Tablet For HIV Treatment Hits Primary Goal
Gilead Sciences announced that its experimental fixed-dose combination tablet of bictegravir/lenacapavir (BIC/LEN) met its primary goal in the Phase 3 ARTISTRY-2 trial for HIV treatment. The drug showed non-inferior efficacy to Biktarvy and was well-tolerated with no new safety concerns. Gilead plans to submit these findings to regulatory authorities and present the detailed results at a future scientific congress.
Dec 15, 2025 • PharmiWeb.com
BULLISH
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
Gilead Sciences announced positive topline results from its Phase 3 ARTISTRY-2 trial, demonstrating that its investigational single-tablet regimen of bictegravir and lenacapavir (BIC/LEN) met the primary endpoint for non-inferiority in HIV treatment compared to BIKTARVY. This novel combination, which combines an integrase strand transfer inhibitor with a first-in-class capsid inhibitor, was generally well tolerated and could expand future treatment options for virologically suppressed adults with HIV. The company plans to use these results, alongside those from the ARTISTRY-1 trial, for regulatory submissions.
Dec 15, 2025 • MarketBeat
SOMEWHAT-BULLISH
Gilead Sciences, Inc. $GILD Shares Bought by Westwood Holdings Group Inc.
Westwood Holdings Group Inc. increased its stake in Gilead Sciences (NASDAQ:GILD) by 3.5% in Q2, boosting its total holdings to 334,052 shares valued at $37 million. This move is part of a broader trend, with other institutional investors like Vanguard Group Inc. and Geode Capital Management LLC also significantly increasing their positions in the biopharmaceutical company. Analysts have given Gilead Sciences a "Moderate Buy" consensus rating with an average price target of $131.54, amidst recent insider stock sales by company directors and CFO.
Dec 15, 2025 • TradingView — Track All Markets
BULLISH
Gilead’s experimental HIV treatment meets main goal in late-stage trial
Gilead Sciences announced that its experimental HIV treatment successfully met its primary objective in a late-stage clinical trial. This development signals a potential advancement in HIV therapy. The company's stock symbol is GILD.
Dec 15, 2025 • Stock Titan
BULLISH
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
Gilead Sciences announced positive topline results from its Phase 3 ARTISTRY-2 trial, showing that an investigational single-tablet regimen of bictegravir and lenacapavir (BIC/LEN) was non-inferior to BIKTARVY for HIV treatment. These findings, combined with results from the ARTISTRY-1 trial, will form the basis for regulatory submissions. The new combination aims to expand treatment options for virologically suppressed adults with HIV.
Dec 15, 2025 • Business Wire
BULLISH
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
Gilead Sciences, Inc. announced positive topline results from the Phase 3 ARTISTRY-2 trial, evaluating a new single-tablet regimen (BIC/LEN) for HIV treatment. The study found BIC/LEN to be statistically non-inferior to BIKTARVY for virologically suppressed adults and generally well-tolerated. These results, combined with ARTISTRY-1 findings, will support regulatory submissions for this investigational treatment.